Andrew Natenshon
YOU?
Author Swipe
View article: Connecting research and community: a methodological framework for investigating CMV transmission in childcare settings
Connecting research and community: a methodological framework for investigating CMV transmission in childcare settings Open
The CMV Transmission and Immune Tracking (TransmIT) Study was developed to address critical gaps in understanding of cytomegalovirus (CMV) transmission dynamics in early education and care (EEC) settings. This two-stage, community-engaged …
View article: Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial
Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial Open
Background This phase 1 trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1647, a messenger RNA (mRNA)–based cytomegalovirus (CMV) vaccine, in CMV-seronegative and -seropositive adults. Methods Participants were random…
View article: 2892. Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial
2892. Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial Open
Background A safe and effective method to protect against cytomegalovirus (CMV) infection is a public health priority. mRNA-1647 is an investigational mRNA-based vaccine against CMV consisting of 6 mRNA sequences encoding 2 CMV antigens (g…
View article: A systematic literature review of the economic and healthcare resource burden of cytomegalovirus
A systematic literature review of the economic and healthcare resource burden of cytomegalovirus Open
CMV and cCMV infections impose a considerable economic impact on different countries, populations, and outcomes. There are substantial evidence gaps where further research is warranted.
View article: A Qualitative Assessment of Clinical Practice Guidelines and Patterns for Congenital Cytomegalovirus in the United States
A Qualitative Assessment of Clinical Practice Guidelines and Patterns for Congenital Cytomegalovirus in the United States Open
Cytomegalovirus (CMV) infection during pregnancy may result in long-term health problems for children with congenital CMV (cCMV). Currently, no prevention or treatment interventions are approved by the Food and Drug Administration for a cC…
View article: A systematic literature review on the humanistic burden of cytomegalovirus
A systematic literature review on the humanistic burden of cytomegalovirus Open
CMV infection can have substantial, lifelong, heterogenous impacts on humanistic outcomes, including health status and QoL, which should be considered when developing and implementing treatment and prevention strategies.
View article: A systematic literature review of the economic and healthcare resource burden of cytomegalovirus
A systematic literature review of the economic and healthcare resource burden of cytomegalovirus Open
Cytomegalovirus (CMV) can infect individuals at any age, including infants, who may contract it from infected mothers (congenital CMV [cCMV]). Whereas CMV infection is typically asymptomatic or causes mild illness in healthy individuals, i…
View article: A systematic literature review on the humanistic burden of cytomegalovirus
A systematic literature review on the humanistic burden of cytomegalovirus Open
Cytomegalovirus (CMV) infection is typically asymptomatic in healthy individuals; however, certain populations are vulnerable to infection and may develop serious sequelae. CMV infection may also have a broad impact on humanistic outcomes,…
View article: 112. Interim Results From a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial of an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults
112. Interim Results From a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial of an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults Open
Background Cytomegalovirus (CMV) is the most common congenital viral infection and can cause severe long-term health consequences, including hearing loss and neurodevelopmental delay. A safe and effective method for prevention of CMV infec…
View article: A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development
A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development Open
View article: 1190. Burden of Congenital Cytomegalovirus Among Newborns/Infants < 2 Years of Age From 2010 to 2020
1190. Burden of Congenital Cytomegalovirus Among Newborns/Infants < 2 Years of Age From 2010 to 2020 Open
Background Congenital cytomegalovirus (cCMV) is a leading cause of preventable congenital birth defects worldwide. In the United States, approximately 1 in 200 infants are born with cCMV and about 10% exhibit symptoms at birth; of those, 4…
View article: Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy
Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy Open
Background Herpes simplex viruses (HSVs) are the main cause of genital ulcers worldwide. GEN-003 is an investigational genital herpes immunotherapy composed of HSV-2 antigens gD2DTMR and ICP4.2, and the saponin-based adjuvant Matrix-M2TM (…
View article: Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo
Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo Open
Background GEN-003 is an investigational genital herpes immunotherapy comprising gD2ΔTMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and …